Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First DataBank Must Create Integratable Data Files Competitor, FTC Says

Executive Summary

First DataBank would be required to set up a competitor in the integratable drug data file market under an April 4 FTC complaint regarding the 1998 acquisition of Medi-Span by Hearst, which also owns First DataBank.

You may also be interested in...



First DataBank FTC Divestiture Order Allows Joint Venture After 3 Years

Hearst subsidiary First DataBank could form a joint venture with Facts and Comparisons after selling the firm its Medi-Span Master Drug Data Base under a proposed settlement with the Federal Trade Commission

First DataBank FTC Divestiture Order Allows Joint Venture After 3 Years

Hearst subsidiary First DataBank could form a joint venture with Facts and Comparisons after selling the firm its Medi-Span Master Drug Data Base under a proposed settlement with the Federal Trade Commission

First DataBank divests Medi-Span

Hearst subsidiary First DataBank sells Medi-Span business to Wolters Kluwer's Facts and Comparisons as part of a proposed settlement with the Federal Trade Commission Nov. 9. Under the settlement, First DataBank customers can terminate their contracts for National Drug Data File products. In April, FTC filed a complaint against Hearst in D.C. federal court alleging that Hearst had monopolized the integrated drug information database market via its acquisition of Medi-Span (1"The Pink Sheet" April 9, p. 6)...

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel